Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 14/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.37 |
| ▸ | TARDBP | Q13148 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258940 | 0.95 | PTGIR (0.35) | PTGIR | |
| SCHEMBL21258966 | 0.92 | PTGIR (0.40) | PTGIRPTGDR | |
| SCHEMBL21258877 | 0.92 | PTGIR (0.37) | PTGIRPTGDRPTGDR2GRM5 | |
| SCHEMBL21258961 | 0.91 | PTGIR (0.35) | PTGIRPTGDRTARDBP | |
| SCHEMBL21258964 | 0.91 | PTGIR (0.43) | PTGIRPTGDRTARDBP | |
| SCHEMBL21258676 | 0.90 | PTGIR (0.38) | PTGIRPTGDRPTGDR2NPSR1 | |
| SCHEMBL22781926 | 0.89 | MEN1 (0.35) | TARDBPAGTR2 | |
| SCHEMBL21258693 | 0.89 | PTGDR (0.33) | PTGIRPTGDR | |
| SCHEMBL21258705 | 0.89 | PTGIR (0.35) | PTGIR | |
| SCHEMBL21258913 | 0.88 | PTGIR (0.35) | PTGIRPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | CHINESE PLA GENERAL HOSPITAL (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | MEDSHINE DISCOVERY INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3750879-A1 | PROSTACYCLIN RECEPTOR AGONIST | Medshine Discovery Inc. (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154363-A1 | PROSTACYCLIN RECEPTOR AGONIST | 南京明德新药研发有限公司 | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087168-A1 | PROSTACYCLIN RECEPTOR AGONIST | PTGIR, TBXA2R, PTGFR | PTGIR 1/4885PTGDR 9/4885TARDBP 4874/4885 |
| US-20210338665-A1 | MEDICAL USE OF PROSTACYCLIN RECEPTOR AGONIST | PTGIR, CYP11B2, PDE8A | PTGIR 1/4885PTGDR 29/4885TARDBP 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.